Science News Study Reveals How Immunotherapy Treatment Produces Exceptional Response in Some Melanoma Patients LatestLY

Columbus [Ohio], April 17 (ANI): A startling 89 per cent of desmoplastic melanoma patients in a nationwide clinical study responded to immunotherapy (pembrolizumab) alone, indicating that many patients could avoid the potential side effects of combination therapies and achieve disease control with this course of treatment. Desmoplastic melanoma is a…Read More